Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. more
Time Frame | NBIX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.12% | -0.33% | -1.49% |
1-Month Return | 7.41% | -4.57% | -0.37% |
3-Month Return | 17.2% | -9.96% | 3.89% |
6-Month Return | 2.18% | -5.67% | 9.34% |
1-Year Return | 4.07% | 2.53% | 25.19% |
3-Year Return | 61.59% | -1.43% | 24.7% |
5-Year Return | 25.19% | 34.73% | 85.39% |
10-Year Return | 540.08% | 102.14% | 187.19% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 788.10M | 1.05B | 1.13B | 1.49B | 1.89B | [{"date":"2019-12-31","value":41.76,"profit":true},{"date":"2020-12-31","value":55.42,"profit":true},{"date":"2021-12-31","value":60.07,"profit":true},{"date":"2022-12-31","value":78.89,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 7.40M | 10.10M | 14.30M | 23.20M | 39.70M | [{"date":"2019-12-31","value":18.64,"profit":true},{"date":"2020-12-31","value":25.44,"profit":true},{"date":"2021-12-31","value":36.02,"profit":true},{"date":"2022-12-31","value":58.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 780.70M | 1.04B | 1.12B | 1.47B | 1.85B | [{"date":"2019-12-31","value":42.26,"profit":true},{"date":"2020-12-31","value":56.07,"profit":true},{"date":"2021-12-31","value":60.58,"profit":true},{"date":"2022-12-31","value":79.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 99.06% | 99.03% | 98.74% | 98.44% | 97.90% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.97,"profit":true},{"date":"2021-12-31","value":99.67,"profit":true},{"date":"2022-12-31","value":99.37,"profit":true},{"date":"2023-12-31","value":98.82,"profit":true}] |
Operating Expenses | 554.10M | 708.30M | 911.40M | 1.22B | 1.60B | [{"date":"2019-12-31","value":34.71,"profit":true},{"date":"2020-12-31","value":44.37,"profit":true},{"date":"2021-12-31","value":57.09,"profit":true},{"date":"2022-12-31","value":76.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 219.15M | 318.90M | 196.90M | 249.00M | 250.90M | [{"date":"2019-12-31","value":68.72,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":61.74,"profit":true},{"date":"2022-12-31","value":78.08,"profit":true},{"date":"2023-12-31","value":78.68,"profit":true}] |
Total Non-Operating Income/Expense | (204.61M) | (89.10M) | (26.90M) | (42.20M) | 76.60M | [{"date":"2019-12-31","value":-267.12,"profit":false},{"date":"2020-12-31","value":-116.32,"profit":false},{"date":"2021-12-31","value":-35.12,"profit":false},{"date":"2022-12-31","value":-55.09,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 46.50M | 106.70M | 101.40M | 213.90M | 332.10M | [{"date":"2019-12-31","value":14,"profit":true},{"date":"2020-12-31","value":32.13,"profit":true},{"date":"2021-12-31","value":30.53,"profit":true},{"date":"2022-12-31","value":64.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | 9.50M | (300.60M) | 11.80M | 59.40M | 82.40M | [{"date":"2019-12-31","value":11.53,"profit":true},{"date":"2020-12-31","value":-364.81,"profit":false},{"date":"2021-12-31","value":14.32,"profit":true},{"date":"2022-12-31","value":72.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | 37.00M | 407.30M | 89.60M | 154.50M | 249.70M | [{"date":"2019-12-31","value":9.08,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22,"profit":true},{"date":"2022-12-31","value":37.93,"profit":true},{"date":"2023-12-31","value":61.31,"profit":true}] |
Income From Continuous Operations | 37.01M | 407.30M | 89.60M | 154.50M | 191.00M | [{"date":"2019-12-31","value":9.09,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22,"profit":true},{"date":"2022-12-31","value":37.93,"profit":true},{"date":"2023-12-31","value":46.89,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 37.00M | 407.30M | 89.60M | 154.50M | 249.70M | [{"date":"2019-12-31","value":9.08,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22,"profit":true},{"date":"2022-12-31","value":37.93,"profit":true},{"date":"2023-12-31","value":61.31,"profit":true}] |
EPS (Diluted) | 0.33 | 1.30 | 1.32 | 1.53 | 2.42 | [{"date":"2019-12-31","value":13.64,"profit":true},{"date":"2020-12-31","value":53.72,"profit":true},{"date":"2021-12-31","value":54.55,"profit":true},{"date":"2022-12-31","value":63.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
NBIX | |
---|---|
Cash Ratio | 2.86 |
Current Ratio | 4.37 |
Quick Ratio | 4.26 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NBIX | |
---|---|
ROA (LTM) | 11.80% |
ROE (LTM) | 16.35% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NBIX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.23 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.77 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NBIX | |
---|---|
Trailing PE | 36.41 |
Forward PE | 19.05 |
P/S (TTM) | 6.16 |
P/B | 5.10 |
Price/FCF | 92 |
EV/R | 5.75 |
EV/Ebitda | 23.19 |
PEG | 0.32 |
Neurocrine Biosciences Inc (NBIX) share price today is $136.53
Yes, Indians can buy shares of Neurocrine Biosciences Inc (NBIX) on Vested. To buy Neurocrine Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NBIX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Neurocrine Biosciences Inc (NBIX) via the Vested app. You can start investing in Neurocrine Biosciences Inc (NBIX) with a minimum investment of $1.
You can invest in shares of Neurocrine Biosciences Inc (NBIX) via Vested in three simple steps:
The 52-week high price of Neurocrine Biosciences Inc (NBIX) is $157.98. The 52-week low price of Neurocrine Biosciences Inc (NBIX) is $110.95.
The price-to-earnings (P/E) ratio of Neurocrine Biosciences Inc (NBIX) is 36.408
The price-to-book (P/B) ratio of Neurocrine Biosciences Inc (NBIX) is 5.10
The dividend yield of Neurocrine Biosciences Inc (NBIX) is 0.00%
The market capitalization of Neurocrine Biosciences Inc (NBIX) is $13.82B
The stock symbol (or ticker) of Neurocrine Biosciences Inc is NBIX